TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Dogwood Therapeutics ( (DWTX) ) has provided an announcement.
On June 27, 2025, Dogwood Therapeutics, Inc. announced that its Board of Directors approved a salary increase for Angela Walsh, the Chief Financial Officer. Her salary was raised from $279,916 to $321,903 annually, effective July 1, 2025, following a review of compensation levels for similar roles in peer companies.
The most recent analyst rating on (DWTX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Dogwood Therapeutics stock, see the DWTX Stock Forecast page.
Spark’s Take on DWTX Stock
According to Spark, TipRanks’ AI Analyst, DWTX is a Neutral.
Dogwood Therapeutics’ overall stock score reflects its financial challenges typical of early-stage biotech firms, with no revenue and significant reliance on external financing. However, the recent debt conversion strengthens the balance sheet and boosts investor confidence. Technical indicators suggest neutral momentum, with a speculative valuation.
To see Spark’s full report on DWTX stock, click here.
More about Dogwood Therapeutics
Average Trading Volume: 858,649
Technical Sentiment Signal: Sell
Current Market Cap: $9.46M
Learn more about DWTX stock on TipRanks’ Stock Analysis page.